Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.40 |
| ▸ | CDK4 | P11802 | 7/20 | 0.37 |
| ▸ | CCND1 | P24385 | 7/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969102 | 0.84 | CRHR1 (0.46) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7446420 | 0.83 | CDK4 (0.49) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7427284 | 0.81 | GLP1R (0.41) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7437075 | 0.75 | CDK4 (0.51) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7964151 | 0.74 | CRHR1 (0.43) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7437929 | 0.72 | CDK4 (0.47) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5707841 | 0.70 | CDK4 (0.46) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7437551 | 0.66 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL8122461 | 0.65 | CDK4 (0.51) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7968810 | 0.65 | CDK4 (0.39) | CRHR1CDK4CCND1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218397-B1 | FOR THERAPY OF STRESS-RELATED ILLNESSES, SUCH AS STRESS-INDUCED DEPRESSION, ANXIETY, AND HEADACHE; ABDOMINAL BOWEL SYNDROME; INFLAMMATORY DISEASES; IMMUNE SUPPRESSION; ALZHEIMER'S DISEASE; GASTRONINTESTINAL DISEASES | PFIZER INC | 2001-04-17 | — | — | US | disclosed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | disclosed |